secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001558370-24-001987
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones
--------------------------------------------------------------------------------

- Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).
- FY 2023 collaboration revenue $250.0M (vs $40.9M), net income $132.3M (vs loss $46.4M).
- Pro-forma cash $431M after Novartis $100M and Jan 2024 $100M public offering; runway into 2027.
- Selected development candidates: SOD1 ALS gene therapy (IND mid-2025) and Friedreich's ataxia (triggered $5M milestone, clinic 2025).
- Novartis collaboration: $80M upfront + $20M equity, up to $1.2B milestones; VY-TAU01 IND expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024001987/0001558370-24-001987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837024001987/vygr-20240228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-001987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer